Actavia Life Sciences, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RASP research report →
Companywww.rasna.com
Actavia Life Sciences, Inc. is a biotechnology company, which engages in the development of therapeutics for the treatment of leukemia and lymphoma diseases. It also develops small molecule drug candidates that focus on treating acute myeloid leukemia.
- CEO
- Keeren Shah
- IPO
- 2015
- Employees
- 1
- HQ
- New York City, NY, US
Price Chart
Valuation
- Market Cap
- $385.91K
- P/E
- -0.07
- P/S
- 0.00
- P/B
- -0.15
- EV/EBITDA
- -1.37
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 243.82%
- ROIC
- 242.87%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-4,443,000 · -546.72%
- EPS
- $-0.01 · 23.00%
- Op Income
- $-4,238,000
- FCF YoY
- 97.28%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -64.36
- Avg Volume
- 93.04
Get TickerSpark's AI analysis on RASP
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our RASP Coverage
We haven't published any research on RASP yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate RASP Report →